A shortcoming of conventional assays used for the study of HIV-1-specific antibodies is that they often fail to detect activities associated with complement activation and Fc receptor binding that could influence virus replication in vivo. Complement-activating antibodies enhance the formation of complement-coated HIV-1 that resists complement lysis and binds complement receptors (CR) on a variety of cell types, including follicular dendritic cells, monocytes, macrophages, B lymphocyte and red blood cells. Antibody-coated virus may further interact with monocytes and macrophages through Fc receptors (FcR) independently of complement. Each of theses activities may be regulated by the immunoglobulin class and subclass and could influence HIV-1 replication in vivo by; 1) increasing virus entry or post-entry replication leading to infection-enhancement, 2) expanding tropism to cells that have little or no CD4 antigen on their surface, 3) trapping complement-opsonized virus on the surface of follicular dendritic cells and 4) clearing virus through the mononuclear phagocytic system. We will study immunologic mechanisms of complement activation and interactions of HIV-1 with CR and FcR during acute primary infection as a unique setting in which to explore their possible contribution to virus replication or clearance. One approach will be to determine whether complement activation in vivo correlates with immunological, virological and clinical profiles. Additional studies will characterize the appearance of circulating HIV-1 immune complexes and will assess whether their biochemical content and biological properties are predicted by serologic correlates. IgA, IgM and IgG production will be assessed to determine their timing of appearance and virus antigen specificity/ IgG will be further delineated with respect to subclasses. Antibodies will be assessed for complement activation using patient isolates and autologous sera in quantitative immunoassays. Infection- enhancement will be evaluated in assays that detect both complement- dependent and -independent mechanisms of antibody-enhanced HIV-1 infection. These studies will provide critical information on serological correlates of HIV-1 pathogenesis that predict interactions with CR and FcR involved in wither virus spread or in control of plasma viremia.

Project Start
2000-09-01
Project End
2002-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
2000
Total Cost
$320,540
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Shen, Xiaoying; Parks, Robert J; Montefiori, David C et al. (2009) In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 83:3617-25
Tomaras, Georgia D; Yates, Nicole L; Liu, Pinghuang et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82:12449-63
Alam, S Munir; Scearce, Richard M; Parks, Robert J et al. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82:115-25
Montefiori, David C; Altfeld, Marcus; Lee, Paul K et al. (2003) Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol 170:3906-14
Montefiori, D C; Hill, T S; Vo, H T et al. (2001) Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75:10200-7
Tokunaga, K; Greenberg, M L; Morse, M A et al. (2001) Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 75:6776-85
Ortiz, G M; Wellons, M; Brancato, J et al. (2001) Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 98:13288-93
Tomaras, G D; Greenberg, M L (2001) CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. Front Biosci 6:D575-98
Demarest, J F; Jack, N; Cleghorn, F R et al. (2001) Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 17:1333-44
Tomaras, G D; Lacey, S F; McDanal, C B et al. (2000) CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc Natl Acad Sci U S A 97:3503-8

Showing the most recent 10 out of 12 publications